Literature DB >> 11873110

A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection.

Andrew J Muir1, Dawn Provenzale.   

Abstract

GOAL: To assess the number of chronic hepatitis C patients eligible for therapy.
BACKGROUND: Recent studies have shown improved response rates to treatment of chronic hepatitis C infection. However, treatment with interferon alfa has major side effects, and many patients may not be eligible for therapy. STUDY: One hundred consecutive patients with positive hepatitis C serologies at the Durham Veterans Affairs Medical Center were evaluated. Medical records were reviewed, and the patients were interviewed. Patients were considered ineligible for therapy if they had severe mental illness, hazardous alcohol consumption, current drug abuse, decompensated cirrhosis, dementia, terminal illness, diabetic ketoacidosis, and severe cardiac or pulmonary disease or if they were homeless.
RESULTS: Of the 100 patients, 92% were male and 51% were African American. The mean age was 47.3 +/- 5.6 years. Only 32 of the 100 patients were eligible for therapy. Hazardous alcohol consumption was present in 44%. Major depressive symptoms were present in 12%.
CONCLUSIONS: The minority of chronic hepatitis C patients were eligible for therapy. Significant rates of hazardous alcohol consumption and psychiatric disorders were present. For these patients to complete or become eligible for therapy, a multidisciplinary approach with psychiatric and substance abuse treatment will be necessary.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11873110     DOI: 10.1097/00004836-200203000-00015

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  24 in total

1.  Correlates of hazardous drinking among Veterans with and without hepatitis C.

Authors:  Megan Oser; Michael Cucciare; John McKellar; Kenneth Weingardt
Journal:  J Behav Med       Date:  2012-01-11

2.  Effectiveness of a screening program for hepatitis C.

Authors:  Ramsey C Cheung; Barbara A Cunningham; Allen D Cooper
Journal:  Dig Dis Sci       Date:  2006-04-27       Impact factor: 3.199

3.  Utilization and antiviral therapy in patients with chronic hepatitis C: analysis of ambulatory care visits in the US.

Authors:  Ramsey Cheung; Ajitha Mannalithara; Gurkirpal Singh
Journal:  Dig Dis Sci       Date:  2010-02-26       Impact factor: 3.199

4.  Hepatitis C treatment completion rates in routine clinical care.

Authors:  Adeel A Butt; Kathleen A McGinnis; Melissa Skanderson; Amy C Justice
Journal:  Liver Int       Date:  2009-11-04       Impact factor: 5.828

Review 5.  Alcohol use and hepatitis C.

Authors:  Marion G Peters; Norah A Terrault
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

6.  Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence.

Authors:  D M Evon; D A Esserman; J E Bonner; T Rao; M W Fried; C E Golin
Journal:  J Viral Hepat       Date:  2013-02-25       Impact factor: 3.728

7.  A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment.

Authors:  Donna M Evon; Kelly Simpson; Scott Kixmiller; Joseph Galanko; Karen Dougherty; Carol Golin; Michael W Fried
Journal:  Am J Gastroenterol       Date:  2011-07-19       Impact factor: 10.864

8.  Determinants of antiviral treatment initiation in a hepatitis C-infected population benefiting from universal health care coverage.

Authors:  Romain Moirand; Marc Bilodeau; Suzanne Brissette; Julie Bruneau
Journal:  Can J Gastroenterol       Date:  2007-06       Impact factor: 3.522

9.  Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study.

Authors:  Christine M Rousseau; George N Ioannou; Jeffrey A Todd-Stenberg; Kevin L Sloan; Meaghan F Larson; Christopher W Forsberg; Jason A Dominitz
Journal:  Am J Public Health       Date:  2008-04-01       Impact factor: 9.308

10.  High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities.

Authors:  Donna M Evon; Amit Verma; Karen A Dougherty; Betty Batey; Mark Russo; Steven Zacks; Roshan Shrestha; Michael W Fried
Journal:  Dig Dis Sci       Date:  2007-03-30       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.